Introduction
The occurrence of an abdominal aortic aneurysm (AAA) in a patient may be seen as one out of many end-stage conditions of an atherosclerotic disease. The benefit and rationale for screening and endovascular aneurysm repair (EVAR) of AAA in asymptomatic patients has been questioned lately, 1,2 as it is very unlikely that screening can reduce the all-cause mortality, the preferred endpoint, in patients with AAA. 3 Therefore, preoperative evaluation and patient selection have become very important issues and reports on long-term outcome and prognostic factors in observational studies after EVAR will be needed now and in the future. Preoperative cardiac assessment seems to be most important, since cardiac complications represent the major cause of peri-operative morbidity and mortality in patients undergoing vascular surgery. 4 Electrocardiogram (ECG) and echocardiography prior to either open or endovascular repair of AAA have, in both our and other institutions, been standard instruments for the evaluation of cardiac function. However, the prognostic value of each specific cardiac parameter on long-term all-cause mortality remains unclear. The aim of this study was to analyze cardiovascular predictors for long-term mortality after standard EVAR with the non-ruptured AAA between May 1998 and February 2006. The patients were identified in the prospective database for endovascular interventions. Complementary data were retrieved from patient records.
Echocardiography
Echocardiography was included in the standardized workup. Transthoracic echocardiographic examinations were performed with Sonos 2500 or Sonons 5500 (Philips, Eindhoven, The Netherlands) by highly trained personal. Left ventricular ejection fraction (EF), regional wall motion abnormalities and presence of left ventricular hypertrophy (LVH) were assessed visually. 5, 6 EF was not determined with higher precision than 5% and therefore graded semi-quantitatively as follows: normal (≥ 55%), mildly reduced (45-50%), moderately reduced (35-40%), severely reduced (< 35%). Aortic valve stenosis was defined as a maximal systolic velocity > 2.5 m/s; the velocity ratio was used if EF was reduced. 7 Aortic and mitral valve insufficiencies were graded as mild, moderate or severe. 8 Severe valve disease was defined as presence of either aortic valve insufficiency (≥ moderate), mitral valve insufficiency (≥ moderate), or presence of aortic valve stenosis. No patient had mitral valve stenosis. Maximal systolic pulmonary artery pressure was estimated from continuous-wave Doppler measurement of tricuspid regurgitation, with use of the modified Bernoulli equation, and by adding estimated right atrial pressure. 9
Electrocardiography
ECGs were usually obtained a few weeks prior to EVAR. All ECGs at rest were interpreted by a specialist in clinical physiology (MD). Evidence of ischemia on ECG was defined as presence of a pathological Q/QS pattern suggesting previous myocardial infarction, ST-segment depression, deep or moderate T-wave inversion, or complete left bundle branch block. 10, 11 Presence of bundle block was also recorded. The ECG was graded as overall normal or pathological.
Evaluation of renal function
The Cockroft-Gault formula includes serum creatinine, age, weight and sex to calculate glomerular filtration rate (GFR). 12 Stages of chronic kidney disease were determined on GFR levels and the National Kidney Foundation guidelines 13 : stage I = GFR > 90 ml/min/1.73 m 2 (normal or increased GFR); stage II = GFR 60-89 ml/min/1.73 m 2 (small decrease in GFR); stage III = GFR 30-59 ml/min/1.73 m 2 (moderate decrease in GFR); stage IV = GFR 15-29 ml/ min/1.73 m 2 (large decrease in GFR); stage V = GFR < 15 ml/min/1.73 m 2 (need for dialysis, end-stage renal disease).
Follow-up
All patients were monitored from the day of EVAR until death or 1 December 2010. The median follow-up time was 68 months. All patients were seen at the outpatient clinic at 1 month and 1 year postoperatively. The patients underwent a contrast-enhanced CT and a plain abdominal film every year. Follow-up mortality data were retrieved from the Swedish Population Registry. The causes of deaths (death certificates) were obtained from the National Board of Health and Welfare. This study was approved by the Research Ethics Committee at the University of Lund.
Other definitions
Hypertension was defined as systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg, or both, at admission. In patients with diabetes mellitus, hypertension was defined as systolic blood pressure > 130 mmHg or diastolic blood pressure > 80 mmHg. Hypertension was also considered if the patient previously had been diagnosed with hypertension or was taking antihypertensive medication. Cerebrovascular disease was considered if there was a history of stroke (cerebral bleeding or infarction) or transient ischemic attack (TIA). Ischemic heart disease was considered if there was a history of myocardial infarction, angina pectoris, coronary artery bypass grafting, or percutaneous coronary angioplasty. Diabetes mellitus was noted if the patient had antidiabetic treatment with diet, oral hypoglycemic agents, or insulin.
Smoking included both current and former tobacco smokers. Anemia was defined as hemoglobin < 134 g/l in men and < 117 g/l in women. A patient with any of the following symptoms or laboratory values was considered unfit for open surgery 14 : severe valve disease, significant arrhythmia, uncontrolled congestive heart failure, forced expiratory vital capacity within 1 second < 1.0 l, PO 2 < 8 kPa, PCO 2 > 6.5 kPa, serum creatinine > 200 µmol/l.
Statistical methods
Data management and statistical analysis were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Analysis was performed on an intention-to-treat basis. Differences in proportions were evaluated using the chisquare test or Kendall's tau-b test and expressed in terms of odds ratios (OR) with 95% confidence intervals (CI) and p-values. Comparisons between groups by using continuous variables were made with the Mann-Whitney U-test. Correlations were calculated with the Spearman rank test. Variables associated with death during follow-up in the univariate analysis were further tested in a multivariate Cox regression model, with all variables (p < 0.1) entered into the model. Associations were expressed in terms of hazard ratios (HR) with 95% CI and p-values. A p-value < 0.05 was considered significant.
Results

Mortality
Among the 304 patients, the 30-day mortality rate was 3.0% (9/304). The mortality until end of follow-up was 54.3% (165/304). The proportion of deaths caused by vascular diseases was 61% (101/165) and the proportion of patients who died from malignant disease was 25% (41/165). Ten and 15 patients died from lung cancer and chronic obstructive pulmonary disease, respectively. Aneurysm-related deaths occurred in 4.9% (15/304) of patients.
Age, sex and co-morbidity in relation to longterm mortality
The median age was 74 years (range 53-89). Baseline characteristics among the 304 study patients are shown in Table 1 . Age 80 years and above, renal insufficiency and anemia were all associated with long-term mortality in the univariate analysis. There was an inverse relation between anemia and GFR (r = -0.256; p < 0.001). Patients considered unfit for open surgery were at higher risk for mortality during follow-up.
Echocardiographic findings in relation to long-term mortality
The echocardiographic evaluations showed that 20.4% (52/255) of the examined patients had a decreased EF and that 7.5% (19/255) had severe valve disease ( Table 2) . Lowered EF, mitral valve insufficiency and the presence of any severe valve disease were associated with long-term mortality.
Electrocardiographic findings in relation to long-term mortality
Nineteen and seven patients had right and left branch bundle block, respectively. ECG was interpreted as pathological in 51% of the examined patients and signs of myocardial ischemia were found in 32% (Table 3 ). Both these ECG findings were found to be highly associated with long-term mortality.
Cardiovascular medication in relation to long-term mortality
The proportion of patients with ongoing cardiovascular medication was 83%. Medication with statins or angiotensin II receptor blockers was associated with decreased long-term mortality, whereas medication with diuretics or digitalis was associated with long-term mortality.
Combined medical severity assessment in relation to long-term mortality
When entering the 10 nominal variables displayed in Table  4 into a Cox regression model, only myocardial ischemia on ECG (HR 1.6 [95% CI 1.1-2.4]; p = 0.018) and anemia (HR 1.5 [95% CI 1.0-2.1]; p = 0.046) were found to be independent predictors for long-term mortality. There was a trend for chronic kidney disease, stage ≥ 3 (HR 1.5 [95% CI 1.0-2.2]; p = 0.051), and age 80 years and above (HR 1.5 [95% CI 1.0-2.4]; p = 0.060) to be independently associated with long-term mortality. When entering age, GFR and EF as continuous instead of nominal variables into the 10-variable multivariate Cox regression analysis, only myocardial ischemia on ECG (p = 0.047) remained as an independent predictor for long-term mortality.
Discussion
There are few, if any, studies with a longer follow-up after EVAR than the present one. The present study identified that finding ischemia on ECG was the most evident predictor of long-term mortality, followed by anemia, chronic kidney disease (stage ≥ 3), and being an octogenarian. Apart from ischemia on ECG, several other cardiac markers were found to be associated with long-term mortality in the univariate analysis such as EF < 55%, mitral valve insufficiency or any severe valve disease, absence of statins at admission, ongoing medication with a diuretic agent or digitalis reflecting congestive heart failure (CHF). Hence, ischemic heart disease defined by ECG, but not by a clinical definition, CHF and lack of proper cardiovascular protective medication at admission were found to be associated with long-term mortality after EVAR. The high proportion of cardiovascular deaths in the present study indicates that the presence and extent of underlying coronary artery disease seems to be a key factor for the longterm survival of patients undergoing EVAR. This suggestion is strengthened by the fact that 92% of the patients undergoing non-cardiac vascular surgery have an abnormal coronary angiography. 15 Preoperative cardiac disease has been shown to be a prognostic variable for late death after major arterial reconstruction in various studies. 16 Estimation and stratification of preoperative cardiac risk prior to EVAR can be performed by using the American College of Cardiology/American Hospital Association guidelines. 17 The intent of this stepwise algorithm guideline was to provide a standardized method of evaluating cardiac risk before non-cardiac surgery and selecting patients at risk for more extensive testing with myocardial stress imaging and/or coronary angiography. The baseline investigations of this guideline, ECG and transthoracic echocardiography, were performed in the present study population, but no specific action was taken in patients showing lowered EF or severe valve disease prior to EVAR. These patients might well have benefitted from an evaluation by the cardiologist, 4 even if there are no data justifying coronary artery revascularization before elective major vascular surgery among patients with stable cardiac symptoms. 18 The impact of renal dysfunction on decreased short-term survival after EVAR has previously been shown. 19, 20 The present study has, not unexpectedly, shown that lower GFR and higher stages of chronic kidney disease were adverse predictors for long-term outcome. Patients with renal failure with the need of dialysis have been found to have the poorest outcome of all EVAR candidates, poor enough to deny EVAR in these patients. 20 The present study results also suggest that renal dysfunction seems to contribute to anemia, which was found in a high proportion of the study patients: 35%. Nevertheless, anemia was found to be another independent factor associated with all-cause mortality. The presence of anemia has received less attention in previous literature, but our data support that the presence or absence of anemia should be included in every risk stratification assessment prior to EVAR. 21 Although the anemia was left unclassified in this study, we do believe that anemia was a proxy for poor general health.
Patients who were on medication with statins at admission had an improved long-term survival at univariate analysis in the present study. The preoperative duration of statin therapy was unknown, however, as well as whether statin therapy was added postoperatively to those patients who were not on statins at admission. Only 35% of the study patients were on statins at admission, and it is possible that this figure might have increased only slightly postoperatively. The patients were included between 1998 and 2006, a period when therapeutic activity with statins among patients with AAA still was far from standard. Whatever, both preoperative 22 and postoperative 23 statin therapy has previously been shown to be associated with improved allcause survival after AAA repair. Interestingly, there was a trend that medication with angiotensin receptor II blocker was associated with decreased long-term mortality in the present study. However, the role of the renin-angiotensin system in aneurysmal disease so far seems to be controversial, with regard to both mortality 24 and expansion rate. 25, 26 Additionally, the present study showed that there was a clear underuse of other cardio-protective medications among the study patients, with only 51% being on antiplatelet therapy at admission, 43% on beta-receptor blockers and 24% on angiotensin-converting enzyme inhibitors. Hence, medical treatment of cardiovascular risk was suboptimal 27 and there seems to be room for much improvement in reducing the cardiovascular morbidity and mortality in patients undergoing EVAR. Awareness of the importance of medical treatment has made us change our preoperative evaluation algorithm, and since 2007 preoperative evaluation of all elective EVAR candidates are performed by both vascular surgeons and vascular physicians at our institution. The most important task of the latter group is to increase the smoking cessation rate, scrutinize if there is a need for further cardiopulmonary workup with echocardiography and spirometry, respectively, and to equip the patient with proper cardiopulmonary protective medication. The intended beneficial effect of this new preoperative standardized evaluation algorithm is under assessment in another on-going, long-term, follow-up study, where the present study data will serve as control.
In conclusion, ischemia on ECG and anemia were independently related to an increased long-term mortality rate after EVAR, and these predictive factors seem to be most important for critical assessment in the preoperative medical work-up.
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